The Manufacturers Life Insurance Company bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 146,854 shares of the company's stock, valued at approximately $1,514,000. The Manufacturers Life Insurance Company owned about 0.21% of Immix Biopharma as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company's stock valued at $1,526,000 after acquiring an additional 31,625 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company's stock worth $84,000 after purchasing an additional 10,950 shares during the last quarter. Imprint Wealth LLC bought a new position in shares of Immix Biopharma in the third quarter worth approximately $141,000. Citadel Advisors LLC purchased a new stake in Immix Biopharma in the third quarter valued at approximately $188,000. Finally, Susquehanna International Group LLP raised its stake in Immix Biopharma by 78.8% in the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company's stock valued at $190,000 after purchasing an additional 40,032 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company's stock.
Immix Biopharma Price Performance
Shares of IMMX opened at $13.83 on Friday. The firm has a market cap of $989.40 million, a P/E ratio of -15.72 and a beta of 0.20. The stock has a 50 day simple moving average of $10.95 and a two-hundred day simple moving average of $9.76. Immix Biopharma, Inc. has a 1 year low of $1.94 and a 1 year high of $15.10.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, equities analysts anticipate that Immix Biopharma, Inc. will post -0.74 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Citigroup reissued a "market outperform" rating on shares of Immix Biopharma in a research note on Friday, August 14th. Morgan Stanley lowered their price objective on shares of Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Lifesci Capital started coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They set an "outperform" rating and a $19.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research report on Friday, July 17th. Finally, Needham & Company LLC started coverage on Immix Biopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $21.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of "Moderate Buy" and an average target price of $21.29.
Read Our Latest Research Report on Immix Biopharma
Immix Biopharma Company Profile
(
Free Report)
Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
